Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tofacitinib citrate
Drug ID BADD_D02237
Description Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Indications and Usage It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.
Marketing Status Prescription
ATC Code L04AA29
DrugBank ID DB08895
KEGG ID D09783
MeSH ID C479163
PubChem ID 10174505
TTD Drug ID D0EG1I
NDC Product Code 42765-036; 52076-6267; 76397-027; 66039-915; 69037-0072; 76397-028; 53747-053; 71052-554; 69218-0700; 11712-895; 49574-523; 14501-0083; 60715-1000; 17337-0079; 76397-026; 73377-084
Synonyms tofacitinib | tasocitinib | tofacitinib citrate | Xeljanz | CP 690,550 | CP690550 | CP-690550 | CP 690550 | CP-690,550
Chemical Information
Molecular Formula C22H28N6O8
CAS Registry Number 540737-29-9
SMILES CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malignant melanoma23.08.01.001; 16.03.01.001--Not Available
Musculoskeletal pain15.03.04.007--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Neutrophil count decreased13.01.06.010--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Opportunistic infection11.01.08.007--Not Available
Paraesthesia17.02.06.005--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Sinus congestion22.04.06.001--Not Available
Skin cancer16.03.02.002; 23.08.02.002--Not Available
Tendonitis15.07.01.003; 12.01.07.007--Not Available
Tuberculosis11.04.01.006--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Vomiting07.01.07.003--
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Prostate cancer21.04.02.002; 16.25.01.001--Not Available
Colorectal cancer16.13.01.002; 07.21.01.002--Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.002--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
The 2th Page    First    Pre   2    Total 2 Pages